Sökning: onr:"swepub:oai:DiVA.org:uu-326223" >
Cytogenetic Risk De...
-
Michelis, Fotios V.Princes Margaret Canc Ctr, Allogene Blood & Marrow Transplant Program, Toronto, ON, Canada.
(författare)
Cytogenetic Risk Determines Outcomes After Allogeneic Transplantation in Older Patients With Acute Myeloid Leukemia in Their Second Complete Remission : A Center for International Blood and Marrow Transplant Research Cohort Analysis
- Artikel/kapitelEngelska2017
Förlag, utgivningsår, omfång ...
-
2017-01-24
-
WILEY,2017
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-326223
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-326223URI
-
https://doi.org/10.1002/cncr.30567DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:135877929URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BACKGROUND Allogeneic hematopoietic cell transplantation (HCT) offers curative potential to a number of older patients with acute myeloid leukemia (AML) in their first complete remission. However, there are limited data in the literature concerning post-HCT outcomes for older patients in their second complete remission (CR2).METHODS The purpose of the current study was to retrospectively investigate within the Center for International Blood and Marrow Transplant Research database parameters influencing post-transplant outcomes for patients 60 years of age or older undergoing HCT for AML in CR2.RESULTS In total, 196 patients from 78 centers were identified; the median age was 64 years (range, 60-78 years). Seventy-one percent had a Karnofsky performance status >= 90 at the time of HCT. Reduced-intensity conditioning regimens were used in 159 patients (81%). A univariate analysis demonstrated a 3-year overall survival (OS) rate of 42% (95% confidence interval [CI], 35%-49%), a leukemia-free survival rate of 37% (95% CI, 30%-44%), a cumulative incidence of nonrelapse mortality of 25% (95% CI, 19%-32%), and a cumulative incidence of relapse (CIR) of 38% (95% CI, 31%-45%). A multivariate analysis demonstrated that cytogenetic risk was the only independent risk factor for OS (P=.023) with a hazard ratio (HR) of 1.14 (95% CI, 0.59-2.19) for intermediate-risk cytogenetics and an HR of 2.32 (95% CI, 1.05-5.14) for unfavorable-risk cytogenetics. For CIR, cytogenetic risk was also the only independent prognostic factor (P=.01) with an HR of 1.10 (95% CI, 0.47-2.56) for intermediate-risk cytogenetics and an HR of 2.98 (95% CI, 1.11-8.00) for unfavorable-risk cytogenetics.CONCLUSIONS Allogeneic HCT is a curative treatment option for older patients with AML in CR2, particularly for those with favorable or intermediate cytogenetic risk.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Gupta, VikasPrinces Margaret Canc Ctr, Allogene Blood & Marrow Transplant Program, Toronto, ON, Canada.
(författare)
-
Zhang, Mei-JieMed Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
(författare)
-
Wang, Hai-LinMed Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA.
(författare)
-
Aljurf, MahmoudMed Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA.;King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.
(författare)
-
Bacher, UlrikeUniv Med Gottingen, Dept Hematol Oncol, Gottingen, Germany.;Univ Canc Ctr Hamburg, Interdisciplinary Clin Stem Cell Transplantat, Hamburg, Germany.
(författare)
-
Beitinjaneh, AmerUniv Miami, Miami, FL USA.
(författare)
-
Chen, Yi-BinMassachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.
(författare)
-
DeFilipp, ZachariahEmory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
(författare)
-
Gale, Robert PeterImperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.
(författare)
-
Kebriaei, PartowUniv Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA.
(författare)
-
Kharfan-Dabaja, MohamedH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.
(författare)
-
Lazarus, Hillard M.Univ Hosp, Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA.
(författare)
-
Nishihori, TaigaH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.
(författare)
-
Olsson, Richard F.Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden(Swepub:uu)riols677
(författare)
-
Oran, BetulImperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.;Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA.
(författare)
-
Rashidi, ArminWashington Univ, Sch Med, Div Oncol, St Louis, MO USA.
(författare)
-
Rizzieri, David A.Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.
(författare)
-
Tallman, Martin S.Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA.
(författare)
-
de Lima, MarcosUniv Hosp, Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA.
(författare)
-
Khoury, H. JeanEmory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
(författare)
-
Sandmaier, Brenda M.Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.;Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
(författare)
-
Weisdorf, DanielUniv Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA.
(författare)
-
Saber, WaelMed Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA.
(författare)
-
Princes Margaret Canc Ctr, Allogene Blood & Marrow Transplant Program, Toronto, ON, Canada.Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Cancer: WILEY123:11, s. 2035-20420008-543X1097-0142
Internetlänk
Hitta via bibliotek
-
Cancer
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Michelis, Fotios ...
-
Gupta, Vikas
-
Zhang, Mei-Jie
-
Wang, Hai-Lin
-
Aljurf, Mahmoud
-
Bacher, Ulrike
-
visa fler...
-
Beitinjaneh, Ame ...
-
Chen, Yi-Bin
-
DeFilipp, Zachar ...
-
Gale, Robert Pet ...
-
Kebriaei, Partow
-
Kharfan-Dabaja, ...
-
Lazarus, Hillard ...
-
Nishihori, Taiga
-
Olsson, Richard ...
-
Oran, Betul
-
Rashidi, Armin
-
Rizzieri, David ...
-
Tallman, Martin ...
-
de Lima, Marcos
-
Khoury, H. Jean
-
Sandmaier, Brend ...
-
Weisdorf, Daniel
-
Saber, Wael
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Cancer
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet